

Anti PD-1 treatment increases [¹⁸F]FDG uptake by cancer cells in a mouse B16F10

melanoma model

Supporting information

Mayu Tomita¹, Hironobu Yasui², Kei Higashikawa², Kohei Nakajima¹, Hideo Takakura¹, Tohru Shiga³, Yuji Kuge², Mikako Ogawa¹

¹Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

²Central Institute of Isotope Science, Hokkaido University, Sapporo, Japan

³Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Corresponding author: Mikako Ogawa, Laboratory of Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan.

Phone: +81-11-706-3767, Fax: +81-11-706-3767.

E-mail: mogawa@pharm.hokudai.ac.jp




Fig. S1

Flow-cytometry analysis of metabolism of glucose. **a**, Flow-cytometry analysis of high expression cells of glucose metabolism markers; GLUT1 and hexokinase II. Values represent percentage of CD45⁻ cancer cells (left) or CD45⁺ immune cells (right) in tumor on day 0 (n = 5).

b, Flow-cytometry analysis of high expression cells of glucose metabolism markers; GLUT1 and hexokinase II of CD45⁺ immune cells in spleen on day 0 (n = 5). Data represent mean ± SEM

Table S1

Complete data about flow-cytometry analysis of high expression cells of glucose metabolism markers; GLUT1 and hexokinase II of CD45⁺ immune cells in spleen on day 7.

Group	Mouse	%GLUT1 ^{high} of CD45 ⁺ cells	%HX2 ^{high} of CD45 ⁺ cells
Treatment	mouse1	99.57	51.55
	mouse2	99.79	51.53
	mouse3	99.96	87.54
	mouse4	99.76	92.89
	mouse5	99.92	92.86
	mouse6	99.62	88.39
	Average	99.77	77.46
	SEM	0.06	8.25
Group	Mouse	%GLUT1 ^{high} of CD45 ⁺ cells	%HX2 ^{high} of CD45 ⁺ cells
Non-treatment	mouse7	99.66	53.40
	mouse8	99.29	55.35
	mouse9	99.74	88.43
	mouse10	99.72	95.62
	mouse11	99.26	91.79
	mouse12	99.44	88.76
	Average	99.52	78.89
	SEM	0.09	7.83